FTC Rips Wyeth, Teva Arguments In Effexor Antitrust Suit

Law360, New York (August 13, 2012, 7:01 PM EDT) -- The Federal Trade Commission on Friday said Wyeth LLC and Teva Pharmaceuticals USA Inc.'s characterization of an authorized generic deal violates antitrust law, as the companies try to escape New Jersey litigation claiming they conspired to the stymie generic versions of the antidepressant Effexor XR.

In a proposed amicus brief, the FTC contends that a branded company's pledge to not launch an authorized generic in competition with a generic company indeed counts as a payment under the Third Circuit's K-Dur decision, which tackled the legality of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.